On August 8, 2023, ELI LILLY AND ($NYSE:LLY) reported their second quarter FY2023 earnings results ending June 30, 2023. Total revenue for the quarter was USD 8312.1 million, representing a 28.1% increase from the same period last year. Net income was USD 1763.2 million, an impressive 85.1% growth from the previous year.
On the day of the announcement, ELI LILLY AND stock opened at $506.0 and closed at $521.6, representing a 14.9% surge in price from the prior closing price of $454.1. This increase in stock price can be attributed to the encouraging financial results reported by the company for the quarter. With such impressive financial results, ELI LILLY AND was able to surpass analysts’ expectations and demonstrate its economic strength. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for LLY. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for LLY. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for LLY. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for LLY are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – LLY Intrinsic Value
At GoodWhale, we have conducted an extensive analysis on the fundamentals of ELI LILLY AND. According to our proprietary Valuation Line, the intrinsic value of ELI LILLY AND share is around $293.3. However, ELI LILLY AND stock is now traded at $521.6, which is overvalued by 77.8%. This means that investors may not be getting the best return on their investment. More…
Risk Rating Analysis
Star Chart Analysis
The competition between Eli Lilly and Co and its competitors is intense. Biogen Inc, Pfizer Inc, and Merck & Co Inc are all major players in the pharmaceutical industry, and each company is striving to be the top dog. Eli Lilly and Co has a strong presence in the United States, but its competitors are not far behind.
Biogen Inc is an American multinational biotechnology company. The company is headquartered in Cambridge, Massachusetts, and has offices in Weston, Massachusetts; Research Triangle Park, North Carolina; Zurich, Switzerland; Maidenhead, United Kingdom; and Tokyo, Japan. Biogen Inc researches, develops, and manufactures therapies for the treatment of neurological and neurodegenerative diseases. The company’s products include AVONEX, TYSABRI, and FAMPYRA.
Pfizer Inc has a market cap of 244.98B as of 2022, a Return on Equity of 24.63%. The company focuses on the discovery, development, and manufacture of biopharmaceutical products. Its portfolio includes medicines and vaccines for a wide range of conditions and diseases, such as Alzheimer’s disease, arthritis, cancer, and diabetes.
– Merck & Co Inc ($NYSE:MRK)
Merck & Co., Inc., d.b.a. Merck Sharp & Dohme (MSD) outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the world. The company was established in 1891 as the United States subsidiary of the German company Merck, which was founded in 1668 by the Merck family. Merck & Co. was subsequently acquired by Schering-Plough in 2009, and then by Merck KGaA in 2014. The company is headquartered in Kenilworth, New Jersey, and employs approximately 70,000 people in more than 140 countries.
Merck’s market cap is 238.43B as of 2022. The company has a Return on Equity of 28.84%. Merck & Co. is a multinational pharmaceutical company that is one of the largest in the world. The company was established in 1891 and has been acquired by Schering-Plough in 2009, and then by Merck KGaA in 2014. Merck & Co. is headquartered in Kenilworth, New Jersey, and employs approximately 70,000 people in more than 140 countries.
ELI LILLY AND reported strong financial results for the second quarter of FY2023, with total revenue reaching USD 8312.1 million and a net income of USD 1763.2 million, a notable year-on-year increase of 28.1% and 85.1%, respectively. This news was received positively in the stock market, as the stock price of the company moved up the same day. The impressive financial performance of ELI LILLY AND indicates a strong investment opportunity for potential investors, as it may be seen as an indication of long-term financial health and profitability.